| Filing Date |
Description |
| 2013-01-10 |
On January 6, 2013, Illumina, Inc. (the “Company”), TP Corporation, a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), Verinata Health, Inc., a Delaware corporation (“Verinata”), an ... |
| 2013-01-10 |
On January 6, 2013, Illumina, Inc. (the “Company”), TP Corporation, a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), Verinata Health, Inc., a Delaware corporation (“Verinata”), an ... |
| 2013-01-09 |
As previously announced, on January 8, 2013, Illumina, Inc. (the “Company”) presented at the J.P. Morgan Healthcare Conference in San Francisco, California. The presentation was webcast on the Company's website, and it will remain availab ... |
| 2013-01-08 |
On January 8, 2013, Illumina announced that it has withdrawn its offer to acquire Complete Genomics, Inc. and has notified the Federal Trade Commission that it is withdrawing its related Hart-Scott- Rodino merger prenotification filing. ... |
| 2013-01-08 |
On January 8, 2013, Illumina announced that it has withdrawn its offer to acquire Complete Genomics, Inc. and has notified the Federal Trade Commission that it is withdrawing its related Hart-Scott- Rodino merger prenotification filing. ... |
| 2012-12-14 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ... |
| 2012-12-13 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ... |
| 2012-12-03 |
On November 27, 2012, Illumina, Inc. made a notification filing with the U.S. Department of Justice and the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with Illumina's proposed acquisitio ... |
| 2012-11-29 |
Effective as of November 26, 2012, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") increased the size of the Board from nine to ten members and elected Robert S. Epstein, M.D., to serve on the Board. Dr. Epstein has been assign ... |
| 2012-11-21 |
99.1
Letter dated November 20, 2012, from Illumina, Inc. to the Board of Directors of Complete Genomics, Inc.
SIGNATURES ... |
